Current Allergy and Asthma Reports

, Volume 4, Issue 2, pp 144–148

The dose-response relationship of inhaled corticosteroids in asthma

Authors

  • Matthew Masoli
    • Medical Research Institute of New Zealand
  • Shaun Holt
    • Medical Research Institute of New Zealand
  • Mark Weatherall
    • Medical Research Institute of New Zealand
  • Richard Beasley
    • Medical Research Institute of New Zealand
Article

DOI: 10.1007/s11882-004-0060-y

Cite this article as:
Masoli, M., Holt, S., Weatherall, M. et al. Curr Allergy Asthma Rep (2004) 4: 144. doi:10.1007/s11882-004-0060-y

Abstract

Inhaled corticosteroids are the only class of asthma medication that can reduce symptoms, improve lung function, reduce the frequency of severe exacerbations, including hospital and ICU admissions, and decrease the risk of mortality. The therapeutic dose range for all clinical outcome measures in adults is 100 to 1000 ώg/d of beclomethasone dipropionate or budesonide, or 50 to 500 ώg/d of fluticasone propionate. Doses in excess of this range are not recommended for routine use because they are likely to increase the risk of systemic side-effects without further major improvement in efficacy. The recommendations are qualified by the recognition that there is considerable individual variability in the response to inhaled corticosteroids in asthma, which would suggest that some patients might obtain greater benefit at higher doses, just as some might obtain maximum benefit at lower doses.

Copyright information

© Current Science Inc 2004